J. Lipid Res. Did you know there is a large type edition? Click here.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Forte, T. M.
Right arrow Articles by Bielicki, J. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Forte, T. M.
Right arrow Articles by Bielicki, J. K.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Journal of Lipid Research, Vol. 43, 477-485, March 2002
Copyright © 2002 by Lipid Research, Inc.

Altered activities of anti-atherogenic enzymes LCAT, paraoxonase, and platelet-activating factor acetylhydrolase in atherosclerosis-susceptible mice

Trudy M. Fortea, Ganesamoorthy Subbanagounderb, Judith A. Berlinerb, Patricia J. Blanchea, Anne O. Clermonta, Zhen Jiaa, Michael N. Odaa, Ronald M. Kraussa, and John K. Bielickia
a Life Sciences Division MS 1-222, Lawrence Berkeley National Laboratory, Berkeley, CA 94720
b Department of Medicine, UCLA School of Medicine, Los Angeles, CA 90024

Correspondence to: Trudy M. Forte, To whom correspondence should be addressed., tmforte{at}lbl.gov (E-mail)

We examined whether the putative anti-atherogenic enzymes LCAT, paraoxonase (PON), and platelet-activating factor acetylhydrolase (PAF-AH) are impaired in 8 week old atherosclerosis susceptible apolipoprotein E (apoE)-/- and LDL receptor (LDLr)-/- mice and whether plasma concentrations of bioactive oxidized phospholipids accumulate in plasma. ApoE-/- mice had reduced (28%) LCAT activity and elevated lysophosphatidylcholine and bioactive oxidized phospholipids (1-palmitoyl-2-oxovaleryl-sn-glycero-3-phosphocholine and 1-palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine) compared with controls on the chow diet. Elevated oxidized phospholipids and reduced LCAT activity may, in part, contribute to spontaneous lesions in these mice on a chow diet. A Western diet decreased LCAT activity further (50% of controls) and PON activity was decreased 38%. The LDLr-/- mice showed normal LCAT activity on chow diet and little accumulation of oxidized phospholipids. On a Western diet, LDLr-/- mice had reduced LCAT activity (21%), but no change in PON activity. All genotypes had reduced PAF-AH activity on the Western diet. ApoE-/- and LDLr-/- mice, but not controls, had elevated plasma bioactive oxidized phospholipids on the Western diet.

We conclude that impairment of LCAT activity and accumulation of oxidized phospholipids are part of an early atherogenic phenotype in these models. — Forte, T. M., G. Subbanagounder, J. A. Berliner, P. J. Blanche, A. O. Clermont, Z. Jia, M. N. Oda, R. M. Krauss, and J. K. Bielicki. Altered activities of anti-atherogenic enzymes LCAT, paraoxonase, and platelet-activating factor acetylhydrolase in atherosclerosis-susceptible mice. J. Lipid Res. 2002. 43: 477–485.

Supplementary key words: apoE deficient mice, LDL receptor deficient mice, high density lipoproteins, atherogenic diet, bioactive oxidized phospholipids


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Lipid Res.Home page
B. J. Van Lenten, A. C. Wagner, C.-L. Jung, P. Ruchala, A. J. Waring, R. I. Lehrer, A. D. Watson, S. Hama, M. Navab, G. M. Anantharamaiah, et al.
Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I
J. Lipid Res., November 1, 2008; 49(11): 2302 - 2311.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
P. G. Yancey, W. G. Jerome, H. Yu, E. E. Griffin, B. E. Cox, V. R. Babaev, S. Fazio, and M. F. Linton
Severely altered cholesterol homeostasis in macrophages lacking apoE and SR-BI
J. Lipid Res., May 1, 2007; 48(5): 1140 - 1149.
[Abstract] [Full Text] [PDF]


Home page
J. Exp. Med.Home page
A. T. Shamshiev, F. Ampenberger, B. Ernst, L. Rohrer, B. J. Marsland, and M. Kopf
Dyslipidemia inhibits Toll-like receptor-induced activation of CD8{alpha}-negative dendritic cells and protective Th1 type immunity
J. Exp. Med., February 19, 2007; 204(2): 441 - 452.
[Abstract] [Full Text] [PDF]


Home page
LupusHome page
M McMahon, J Grossman, W Chen, and B H Hahn
Inflammation and the pathogenesis of atherosclerosis in systemic lupus erythematosus
Lupus, November 1, 2006; 15(11_suppl): 59 - 69.
[Abstract] [PDF]


Home page
J. Biol. Chem.Home page
C. J. Ng, N. Bourquard, V. Grijalva, S. Hama, D. M. Shih, M. Navab, A. M. Fogelman, A. J. Lusis, S. Young, and S. T. Reddy
Paraoxonase-2 Deficiency Aggravates Atherosclerosis in Mice Despite Lower Apolipoprotein-B-containing Lipoproteins: ANTI-ATHEROGENIC ROLE FOR PARAOXONASE-2
J. Biol. Chem., October 6, 2006; 281(40): 29491 - 29500.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
E. Trogan, J. E. Feig, S. Dogan, G. H. Rothblat, V. Angeli, F. Tacke, G. J. Randolph, and E. A. Fisher
Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice.
PNAS, March 7, 2006; 103(10): 3781 - 3786.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
H. Yu, W. Zhang, P. G. Yancey, M. J. Koury, Y. Zhang, S. Fazio, and M. F. Linton
Macrophage Apolipoprotein E Reduces Atherosclerosis and Prevents Premature Death in Apolipoprotein E and Scavenger Receptor-Class BI Double-Knockout Mice
Arterioscler. Thromb. Vasc. Biol., January 1, 2006; 26(1): 150 - 156.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
M. Navab, G.M. Anantharamaiah, S. T. Reddy, S. Hama, G. Hough, J. S. Frank, V. R. Grijalva, V. K. Ganesh, V. K. Mishra, M. N. Palgunachari, et al.
Oral Small Peptides Render HDL Antiinflammatory in Mice and Monkeys and Reduce Atherosclerosis in ApoE Null Mice
Circ. Res., September 16, 2005; 97(6): 524 - 532.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. Navab, G.M. Anantharamaiah, S. T. Reddy, B. J. Van Lenten, A. C. Wagner, S. Hama, G. Hough, E. Bachini, D. W. Garber, V. K. Mishra, et al.
An Oral ApoJ Peptide Renders HDL Antiinflammatory in Mice and Monkeys and Dramatically Reduces Atherosclerosis in Apolipoprotein E-Null Mice
Arterioscler. Thromb. Vasc. Biol., September 1, 2005; 25(9): 1932 - 1937.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. Navab, G.M. Anantharamaiah, S. T. Reddy, S. Hama, G. Hough, V. R. Grijalva, N. Yu, B. J. Ansell, G. Datta, D. W. Garber, et al.
Apolipoprotein A-I Mimetic Peptides
Arterioscler. Thromb. Vasc. Biol., July 1, 2005; 25(7): 1325 - 1331.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
A. Chait, C. Y. Han, J. F. Oram, and J. W. Heinecke
Thematic review series: The Immune System and Atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease?
J. Lipid Res., March 1, 2005; 46(3): 389 - 403.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
P. J. Barter, S. Nicholls, K.-A. Rye, G.M. Anantharamaiah, M. Navab, and A. M. Fogelman
Antiinflammatory Properties of HDL
Circ. Res., October 15, 2004; 95(8): 764 - 772.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
M. Navab, G. M. Ananthramaiah, S. T. Reddy, B. J. Van Lenten, B. J. Ansell, G. C. Fonarow, K. Vahabzadeh, S. Hama, G. Hough, N. Kamranpour, et al.
Thematic review series: The Pathogenesis of Atherosclerosis The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL
J. Lipid Res., June 1, 2004; 45(6): 993 - 1007.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
J. Lie, R. de Crom, T. van Gent, R. van Haperen, L. Scheek, F. Sadeghi-Niaraki, and A. van Tol
Elevation of plasma phospholipid transfer protein increases the risk of atherosclerosis despite lower apolipoprotein B-containing lipoproteins
J. Lipid Res., May 1, 2004; 45(5): 805 - 811.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
T. Kujiraoka, T. Iwasaki, M. Ishihara, M. Ito, M. Nagano, A. Kawaguchi, S. Takahashi, J. Ishi, M. Tsuji, T. Egashira, et al.
Altered distribution of plasma PAF-AH between HDLs and other lipoproteins in hyperlipidemia and diabetes mellitus
J. Lipid Res., October 1, 2003; 44(10): 2006 - 2014.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
V. G. Cabana, C. A. Reardon, N. Feng, S. Neath, J. Lukens, and G. S. Getz
Serum paraoxonase: effect of the apolipoprotein composition of HDL and the acute phase response
J. Lipid Res., April 1, 2003; 44(4): 780 - 792.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Journal of Biological Chemistry 
 Molecular and Cellular Proteomics   ASBMB Today 
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.